ArticleFrontiers in neurology2023
Diagnosis and therapy of myasthenia gravis-the patients' perspective: a cross-sectional study.
Article in Frontiers in neurology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 19 citations in OpenAlex.
- Gender differences in Myasthenia Gravis in a neuromuscular reference center in Belgium.Acta neurologica Belgica · 2026Article
- Bridging the gap between patient and physician perspectives on management of generalized myasthenia gravis: a Delphi consensus study.Orphanet journal of rare diseases · 2026Article
- Treatment patterns, intensive treatment, and hospitalization-related burden of juvenile generalized myasthenia gravis in Japan: a retrospective cohort study using a hospital-based claims database.Frontiers in neurology · 2026Article
- Factors associated with increased severity of generalized myasthenia gravis among patients in the United States and Europe.Scientific reports · 2025Article
- Appropriate use of steroids for patients with generalized Myasthenia Gravis: an international Delphi study.Therapeutic advances in neurological disorders · 2025Article
- Factors affecting the diagnostic delay of myasthenia gravis.Journal of neurology · 2024Article
- The impact of diagnosis delay on European patients with generalised myasthenia gravis.Annals of clinical and translational neurology · 2024Article
- Patient and care partner perspectives and preferences related to myasthenia gravis treatment: A qualitative study.Health science reports · 2024Article
- Fatigue and associated factors in myasthenia gravis: a nationwide registry study.Journal of neurology · 2024Article
- Epidemiology, Patient Characteristics, and Treatment Patterns of Myasthenia Gravis in Taiwan: A Population-Based Study.Neurology and therapy · 2024Article
- Myasthenia Gravis: utilising cross-platform quantitative content analysis to uncover and validate unmet needs.Frontiers in neurology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The survey aimed to explore patients' perspectives with myasthenia gravis (MG) toward the diagnosis made and the therapy used to treat MG. The survey was conducted with a quantitative method, using the CAWI technique. A total of 321 people participated in the survey. More than half of the respondents (56.4%) had suffered from MG for less than 10 years. In three out of 10 cases (30.9%), the diagnosis of MG lasted 3 years or longer. The diagnostic delay was significantly longer in female respondents than in the males (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.